(Total Views: 557)
Posted On: 01/26/2022 10:45:40 PM
Post# of 153925
Just some example big pharma buy outs of much lesser scaled than cydy which could be major player on so many Major Market indications. Samsung even mentioned as looking at a potential buyout
Even rare disease small biotech bought out for 11.5 billion not that big market rare diseases still demanded big billions. Other buy outs listed below. I know many of them have lower floats but doesnt matter its about market cap.
Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio.
Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB.
Even rare disease small biotech bought out for 11.5 billion not that big market rare diseases still demanded big billions. Other buy outs listed below. I know many of them have lower floats but doesnt matter its about market cap.
Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio.
Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB.
(4)
(0)
